[go: up one dir, main page]

PE20120647A1 - Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular - Google Patents

Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular

Info

Publication number
PE20120647A1
PE20120647A1 PE2011001641A PE2011001641A PE20120647A1 PE 20120647 A1 PE20120647 A1 PE 20120647A1 PE 2011001641 A PE2011001641 A PE 2011001641A PE 2011001641 A PE2011001641 A PE 2011001641A PE 20120647 A1 PE20120647 A1 PE 20120647A1
Authority
PE
Peru
Prior art keywords
prevention
compositions
treatment
methods
cardiovascular disease
Prior art date
Application number
PE2011001641A
Other languages
English (en)
Inventor
Miguel Angel Duarte-Vazquez
Loria Jorge Luis Rosado
Original Assignee
Nucitec Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nucitec Sa De Cv filed Critical Nucitec Sa De Cv
Publication of PE20120647A1 publication Critical patent/PE20120647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) AGENTE REDUCTOR DE COLESTEROL TAL COMO SIMVASTATINA ENTRE 5-140mg; B) UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA TAL COMO ENALAPRIL DE 1-80 mg; C) UN ANTIAGREGANTE PLAQUETARIO TAL COMO ACIDO ACETILSALICILICO DE 20-50 mg. DICHA COMPOSICION FARMACEUTICA ES DE ADMINISTRACION ORAL EN FORMA DE CAPSULA, TABLETA, POLVO DISPERSABLE EN AGUA O BEBIDAS Y ES UTIL EN LA PREVENCION DE ENFERMEDADES CARDIOVASULARES
PE2011001641A 2009-03-13 2010-03-10 Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular PE20120647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16011009P 2009-03-13 2009-03-13

Publications (1)

Publication Number Publication Date
PE20120647A1 true PE20120647A1 (es) 2012-05-31

Family

ID=42727850

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001641A PE20120647A1 (es) 2009-03-13 2010-03-10 Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular

Country Status (8)

Country Link
US (1) US20100234442A1 (es)
EP (1) EP2405747A4 (es)
CA (1) CA2755543A1 (es)
CL (1) CL2011002265A1 (es)
CO (1) CO6420389A2 (es)
MX (1) MX357919B (es)
PE (1) PE20120647A1 (es)
WO (1) WO2010103384A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507460A (zh) * 2012-08-27 2015-04-08 赢创工业集团股份有限公司 抗乙醇影响的抗胃酸药物或保健品组合物
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014178891A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
US9993488B2 (en) 2014-02-20 2018-06-12 Otitopic Inc. Dry powder formulations for inhalation
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EA202192854A1 (ru) * 2019-04-17 2022-01-28 Кардиофарма, Инк. Комбинация фиксированных доз антигипертензивных и снижающих холестерин средств и способ получения

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) * 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
NZ217006A (en) * 1985-07-30 1989-04-26 Glaxo Group Ltd Inhaler for finely divided medicament includes plunger to open medicament container
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622271A (en) * 1995-09-19 1997-04-22 Innovative Premiums Inc. Wall hangable device
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
US6071489A (en) * 1996-12-05 2000-06-06 Samsung Display Device Co., Ltd. Methods of preparing cathode active materials for lithium secondary battery
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6615826B1 (en) * 1999-02-26 2003-09-09 3M Innovative Properties Company Slow spray metered dose inhaler
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2531279A1 (en) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
WO2009010810A2 (en) * 2006-08-07 2009-01-22 Wockhardt Limited Cardiovascular combinations comprising ace and hmg-co-a inhibitors

Also Published As

Publication number Publication date
CL2011002265A1 (es) 2012-07-06
EP2405747A4 (en) 2013-01-16
WO2010103384A1 (en) 2010-09-16
US20100234442A1 (en) 2010-09-16
MX357919B (es) 2018-07-25
CO6420389A2 (es) 2012-04-16
EP2405747A1 (en) 2012-01-18
CA2755543A1 (en) 2010-09-16
MX2011009587A (es) 2011-10-13

Similar Documents

Publication Publication Date Title
PE20120647A1 (es) Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
MX2012005744A (es) Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
UA106634C2 (uk) Тверда фармацевтична дозована форма
BR112013006597A2 (pt) tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
WO2008113066A3 (en) Ubiquinol and alpha lipoic compositions
GEP20156281B (en) Orally administered corticosteroid compositions
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
IN2012DN06720A (es)
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
EP2419138A4 (en) GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
MX2011002065A (es) Composicion farmaceutica a base de progesterona micronizada y sus usos.
WO2011111027A3 (en) Oral dispersible delayed release tablet formulation
EP2643002A4 (en) PHARMACEUTICAL FORMULATIONS WITH CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION
PE20110943A1 (es) Formulacion oral solida de alisquireno
NI201000159A (es) Cápsula para la prevención de enfermedades cardiovasculares.
EP2468771A4 (en) PHARMACEUTICAL COMPOSITION WITH AN ANTIBODY TO HB-EGF AS AN ACTIVE SUBSTANCE
EP2152075A4 (en) METHOD AND COMPOSITIONS FOR PROMOTING THE TRANSPORT OF PHARMACEUTICAL ACTIVE SUBSTANCES TO BONE
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
MX346316B (es) Formulacion farmaceutica o nutraceutica.
GEP20146067B (en) Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Legal Events

Date Code Title Description
FD Application declared void or lapsed